a Multicenter Clinical Trial for the Treatment of Children and Adolescents With Soft Tissue Sarcoma Stage 4
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
Phase II Study to evaluate the response on two blocks of topotecan and carboplatin
Condition or disease
Sarcoma, Soft Tissue
Drug: TopotecanDrug: Carboplatin
Phase II study for patients with chemosensible soft tissue sarcoma stage IV in children and adolescents ; response according to RECIST criteria following two blocks of combination therapy consisting of Topotecan and carboplatin
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
up to 21 Years (Child, Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Soft tissue sarcoma chemosensible, stage IV
age < 21
measurable tumor lesions
Lack of cooperation by the patient
no willingness of follow-up examinations
participation on another clinical trial at the same time